New KDIGO Guidelines recommends increased use of cystatin C

13. Mar 2024 | 5 min read

Moss, 13 March 2024

Gentian Diagnostics (Gentian), a leading manufacturer of cystatin C, is proud to announce its commitment to kidney care following the release of the KDIGO 2024 Clinical Practice Guideline for Chronic Kidney Disease (CKD). The guideline underscores the pivotal role of cystatin C in estimating glomerular filtration rate (GFR) and tailoring treatment decisions based on individual kidney function status, especially when combined with creatinine. The latest guidelines which recommends increased use of cystatin C aims to improve patient care, particularly in scenarios where precise dosing of medications is paramount.
 
Cystatin C-based assessments offer a more reliable estimation of GFR, enabling healthcare providers to make informed decisions tailored to each patient's unique kidney function profile. By leveraging the accuracy of cystatin C alongside creatinine, clinicians can optimize treatment strategies, ensuring that medication dosages are precisely calibrated to individual kidney function status. This advancement is crucial for enhancing patient outcomes and minimizing risks associated with improper dosing.
 
Gentian's dedication to offering high-quality cystatin C aligns well with the standards outlined in the KDIGO 2024 CKD guidelines. The company's focus on precision and reliability in GFR assessments reflects a commitment to excellence in kidney care, empowering healthcare professionals with the tools needed to deliver personalized treatment plans that prioritize patient well-being.
 
As Gentian continues to drive innovation in precision medicine through its diagnostics assay portfolio, the company remains at the forefront of transforming kidney care and improving patient outcomes. By adhering to the latest guidelines and leveraging state-of-the-art solutions, Gentian reaffirms its mission to revolutionize healthcare through advanced diagnostics and personalized treatment approaches.
 
For more information about Gentian Diagnostics and its innovative cystatin C solutions, please visit www.gentian.com

For sales and marketing enquiries
Markus Jaquemar, CCO markus.jaquemar@gentian.com   +47 919 21 709 
 
For investor enquiries
Njaal Kind, CFO 
Njaal.kind@gentian.com   +47 919 06 525

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous immunoassays, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.

You may also read


Mar 21, 2024 - Ole Sørlie

Notice of annual general meeting

Gentian Diagnostics ASA’s annual general meeting will be held on Monday 29 April 2024 at 12:00 at the..